Patent intelligence · US
US 10118932
Solid state forms of spiro-oxindole compounds
Solid state forms of spiro-oxindole compounds
Patent details — US 10118932
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 6, 2018
- Expiration
- Nov 1, 2038
- Applicant
- Xenon Pharmaceuticals Inc.
- Claims
- 11
- CPC classes
- A61K, A61K31/407, A61P, A61P25/00
Quick answer
US 10118932 (Solid state forms of spiro-oxindole compounds) is held by Xenon Pharmaceuticals Inc.. Status: granted. Granted Nov 6, 2018. Expires Nov 1, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Xenon Pharmaceuticals Inc.
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61K, A61K31/407, A61P, A61P25/00, A61P25/08, A61P25/18
More from Xenon Pharmaceuticals Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12319657
Solid state crystalline forms of a selective potassium channel modulator
granted -
US 12178811
Methods of treating depressive disorders
granted -
US 12171759
Methods and uses for treating anhedonia
granted -
US 11957675
Methods and uses for treating anhedonia
granted -
US 11325902
Benzenesulfonamide compounds and their use as therapeutic agents
granted -
US 11299490
Benzenesulfonamide compounds and their use as therapeutic agents
granted -
US 11203572
Substituted benzamides and methods of use thereof
granted -
US 11174268
Benzenesulfonamide compouds and their use as therapeutic agents
granted
Frequently asked questions
What is US patent 10118932?
US 10118932 (Solid state forms of spiro-oxindole compounds) is held by Xenon Pharmaceuticals Inc.. Status: granted. Granted Nov 6, 2018. Expires Nov 1, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10118932?
Xenon Pharmaceuticals Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 106 pharmaceutical patents for this assignee.
When does US 10118932 expire?
Our index shows an expiration date of Nov 1, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.